First oncolytic virus approved for melanoma immunotherapy.

First oncolytic virus approved for melanoma immunotherapy.

Oncoimmunology. 2016;5(1):e1115641

Authors: Pol J, Kroemer G, Galluzzi L

Abstract
On 2015, October 27th, the US Food and Drug Administration (FDA) has officially approved talimogene laherparepvec (T-VEC, also known as OncoVEX(GM-CSF)) for use in melanoma patients with injectable but non-resectable lesions in the skin and lymph nodes. T-VEC (which is commercialized by Amgen, Inc. under the name of Imlygic®) becomes therefore the first oncolytic virus approved for cancer therapy in the US.

PMID: 26942095 [PubMed - as supplied by publisher]

from melanoma2 via als.fakia on Inoreader http://ift.tt/1QxH2Mc
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/21S5FHh
via IFTTT